HR Execs on the Move

Outlook Therapeutics

www.outlooktherapeutics.com

 
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Alicia Tozier
 Senior Vice President of Marketing and Market Access Profile

Similar Companies

OpGen

OpGen, Inc. is a leading innovator in rapid, accurate genomic and DNA analysis systems and services.

Teva parenteral Medicines

Teva parenteral Medicines is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AmProx

AmProx is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Twentyeight-Seven Therapeutics

Twentyeight-Seven Therapeutics is a focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases.

Annovis Bio

Annovis Bio is developing a drug for Alzheimers Disease, Parkinsons Disease and other neurodegenerative diseases that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport.